HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Figures Only Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Related articles in JNM Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Bading, J. R. Articles by Conti, P. S. Search for Related Content PubMed Articles by Bading, J. R. Articles by Conti, P. S.

Blocking Catabolism with Eniluracil Enhances PET Studies of 5-[¹⁸F]Fluorouracil Pharmacokinetics

Departments of Radiology and Biomedical Engineering, University of Southern California, Los Angeles, California; and Glaxo Wellcome, Inc., Research Triangle Park, North Carolina

Noninvasive methods for measuring the pharmacokinetics of chemotherapeutic drugs such as 5-fluorouracil (FU) are needed for individualized optimization of treatment regimens. PET imaging of [¹⁸F]FU (PET/[¹⁸F]FU) is potentially useful in this context, but PET/[¹⁸F]FU is severely hampered by low tumor uptake of radiolabel and rapid catabolism of FU in vivo. Pretreatment with eniluracil (5-ethynyluracil) prevents catabolism of FU. Hypothesizing that suppression of catabolism would enhance PET/[¹⁸F]FU, we examined the effects of eniluracil on the short-term pharmacokinetics of the radiotracer. Methods: Anesthetized rats bearing a subcutaneous rat colorectal tumor were given eniluracil or placebo and injected intravenously 1 h later with [¹⁸F]FU or [³H]FU. In the ¹⁸F studies, dynamic PET image sequences were obtained 0–2 h after injection. Tumors were excised and frozen at 2 h and then analyzed for labeled metabolites by high-performance liquid chromatography. Biodistribution of radiolabel was determined by direct tissue assay. Results: Eniluracil improved tumor visualization in PET images. With eniluracil, tumor standardized uptake values ([activity/g]/[injected activity/g body weight]) increased from 0.72 ± 0.06 (mean ± SEM; n = 6) to 1.57 ± 0.20 (n = 12; P < 0.01), and tumor uptake increased by factors of 2 or more relative to plasma (P < 0.05) and bone, liver, and kidney (P < 0.01). Without eniluracil (n = 5), 57% ± 4% of recovered radiolabel in tumor at 2 h was on catabolites, with the rest divided among FU (2% ± 1%), anabolites of FU (38% ± 7%), and unidentified peaks (4% ± 2%). With eniluracil (n = 8), catabolites, FU, and anabolites comprised 2% ± 1%, 41% ± 5%, and 57% ± 4%, respectively, of the recovered radiolabel in tumors. Conclusion: Eniluracil increased tumor accumulation of ¹⁸F relative to host tissues and fundamentally changed the biochemical significance of that accumulation. With catabolism suppressed, tumor radioactivity reflected the therapeutically relevant aspect of FU pharmacokinetics—namely, uptake and anabolic activation of the drug. With this approach, it may be feasible to measure the transport and anabolism of [¹⁸F]FU in tumors by kinetic modeling and PET. Such information may be useful in predicting and increasing tumor response to FU.

Key Words: colorectal cancer • chemotherapy • 5-[¹⁸F]fluorouracil • PET • pharmacokinetics

Received Sep. 8, 1999; revision accepted Jan. 12, 2000.

For correspondence or reprints contact: James R. Bading, PhD, PET Imaging Science Center, University of Southern California, 1510 San Pablo St., Ste. 350, Los Angeles, CA 90033-4609.

Related articles in JNM:

Enzyme Inhibition as an Aid to Simplify Pharmacokinetic Measurements?

Tim J. Tewson
JNM 2000 41: 1725-1726. [Full Text]  

This article has been cited by other articles:

				J. R. Bading, P. B. Yoo, J. D. Fissekis, M. M. Alauddin, D. Z. D'Argenio, and P. S. Conti Kinetic Modeling of 5-Fluorouracil Anabolism in Colorectal Adenocarcinoma: A Positron Emission Tomography Study in Rats Cancer Res., July 1, 2003; 63(13): 3667 - 3674. [Abstract] [Full Text] [PDF]